These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36692029)

  • 1. Perceptions of COVID-19 risk during the pandemic: perspectives from people seeking medication for opioid use disorder.
    Clingan SE; Cousins SJ; Lin C; Nguyen TE; Hser YI; Mooney LJ
    Ann Med; 2023 Dec; 55(1):480-489. PubMed ID: 36692029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experiences of people with opioid use disorder during the COVID-19 pandemic: A qualitative study.
    Galarneau LR; Hilburt J; O'Neill ZR; Buxton JA; Scheuermeyer FX; Dong K; Kaczorowski J; Orkin AM; Barbic SP; Bath M; Moe J; Miles I; Tobin D; Grier S; Garrod E; Kestler A
    PLoS One; 2021; 16(7):e0255396. PubMed ID: 34324589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.
    Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Scherer E; Marsch LA
    J Subst Abuse Treat; 2020 Apr; 111():54-66. PubMed ID: 32076361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Qualitative Exploration of the Functional, Social, and Emotional Impacts of the COVID-19 Pandemic on People Who Use Drugs.
    Kelly EL; Reed MK; Schoenauer KM; Smith K; Scalia-Jackson K; Kay Hill S; Li E; Weinstein L
    Int J Environ Res Public Health; 2022 Aug; 19(15):. PubMed ID: 35955107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race, trust, and COVID-19 vaccine hesitancy in people with opioid use disorder.
    Sullivan MC; Mistler C; Copenhaver MM; Wickersham JA; Ni Z; Kim RS; Shrestha R
    Health Psychol; 2022 Feb; 41(2):115-120. PubMed ID: 34855415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambivalence and Stigma Beliefs About Medication Treatment Among Young Adults With Opioid Use Disorder: A Qualitative Exploration of Young Adults' Perspectives.
    Bagley SM; Schoenberger SF; dellaBitta V; Lunze K; Barron K; Hadland SE; Park TW
    J Adolesc Health; 2023 Jan; 72(1):105-110. PubMed ID: 36216678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attitudes Toward COVID-19 Vaccination Among Pregnant Persons in Urban Hospital-Affiliated Practices: Exploring Themes in Vaccine Hesitancy.
    Gibson A; Rand C; Olson-Chen C
    Matern Child Health J; 2023 Oct; 27(10):1855-1863. PubMed ID: 37486448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
    Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
    Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
    [No Abstract]   [Full Text] [Related]  

  • 12. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative insight into the perceptions and COVID-19 vaccine hesitancy among Pakistani pharmacists.
    Yaseen MO; Saif A; Khan TM; Yaseen M; Saif A; Bukhsh A; Shahid MN; Alsenani F; Tahir H; Ming LC; Amin MU; Suleiman AK; Al-Worafi YM; Baig MR; Saeed Imran M; Jaber AA
    Hum Vaccin Immunother; 2022 Dec; 18(1):2031455. PubMed ID: 35192781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.
    Schiff DM; Work EC; Muftu S; Partridge S; MacMillan KDL; Gray JR; Hoeppner BB; Kelly JF; Greenfield SF; Jones HE; Wilens TE; Terplan M; Bernstein J
    J Subst Abuse Treat; 2022 Aug; 139():108765. PubMed ID: 35341614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid-Related Trends in Active Duty Service Members During the Coronavirus Disease 2019 Pandemic.
    Sorensen IS; Susi A; Andreason P; Hisle-Gorman E; Jannace KC; Krishnamurthy J; Chokshi B; Dorr M; Wolfgang AS; Nylund CM
    Mil Med; 2023 Nov; 188(Suppl 6):567-574. PubMed ID: 37948265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 vaccination coverage and vaccine hesitancy among people with opioid use disorder in Barcelona, Spain.
    Vallecillo G; Durán X; Canosa I; Roquer A; Martinez MC; Perelló R
    Drug Alcohol Rev; 2022 Sep; 41(6):1311-1318. PubMed ID: 35668697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose.
    Klemperer EM; Wreschnig L; Crocker A; King-Mohr J; Ramniceanu A; Brooklyn JR; Peck KR; Rawson RA; Evans EA
    J Subst Use Addict Treat; 2023 Sep; 152():209103. PubMed ID: 37311520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A qualitative study exploring the relationship between mothers' vaccine hesitancy and health beliefs with COVID-19 vaccination intention and prevention during the early pandemic months.
    Walker KK; Head KJ; Owens H; Zimet GD
    Hum Vaccin Immunother; 2021 Oct; 17(10):3355-3364. PubMed ID: 34187310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Use Disorder and Overdose in the First Year Postpartum: A Rapid Scoping Review and Implications for Future Research.
    Frankeberger J; Jarlenski M; Krans EE; Coulter RWS; Mair C
    Matern Child Health J; 2023 Jul; 27(7):1140-1155. PubMed ID: 36840785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient brokering in for-profit substance use disorder treatment: a qualitative study with people with opioid use disorder and professionals in the field.
    Clingan SE; D'Ambrosio BM; Davidson PJ
    BMC Health Serv Res; 2023 Nov; 23(1):1214. PubMed ID: 37932740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.